Found some interesting possible connections on Alan Colliers linkedin page. He is following 7 companies, 2 he is CEO of, 2 are the schools he attended, 1 is Virgin Galactic (Branson is also listed as influenced by), and the last two which are possibly relevant to the company. The first is Charles River Laboratories, the largest provider of pre clinical and clinical support in the world. The second is Stemcyte cord blood bank, one of the largest providers of core blood in the world.
https://www.linkedin.com/in/collieralan/detai...companies/
Obvious what the connection may be to Charles River Laboratories but a little research into Stemcyte really got me thinking.
Stemcyte is extracting and expanding stem cells derived from umbilical cord blood. As I researched the processes they are using and the expansion rates it was clear how Endonovo could be on the radar of this company. The are using a starch based solution with sugars, proteins and biologics to create a natural replication environment. It is a slow process which is creating 2 dimensional stem cells. They are bragging about an expansion rate of 14-44 fold.
If you are familiar with the Cytotronics platform you know that Endonovo is able to produce biologically superior stem cells in a 6 day period with an 80 fold expansion rate and because they are grown in a non gravitational atmosphere the are 3 dimensional cells.
I wonder if Stemcyte would be interested in doubling their expansion rate in a much quicker time frame. In 2015 Endonovo announces a corporate licensing program which in addition to licensing the technology also sought partnerships for development. They filed patents and continuation patents shortly after.
On Stemcyte's company description under current projects is this statement, "StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies". Now to me there are a few key words in that statement, "involved in" and "new". If this was a project that was solely being run by Stemcyte it would be phrased is developing not involved in development. The new would definitely classify a technology that is less than 2 years old.
Look at the description on the patent Endonovo applied for in Oct 2015.
The perivascular cell mixture (the "Cell Mixture"
is created using the Company's Cytotronics™ platform and the co-culture of immunologically privileged and modulatory stem cells from a portion of the human umbilical cord along with adipose stem cells and a mixture of cord blood cells to create an off-the-shelf therapeutic product that can be stored indefinitely in a low temperature freezer and used to treat blood-related disorders.
This patent is right at the 2 year time frame and could be granted any day now.
Some things to ponder as we wait for these preclinical results of the Immunotronics platform, which honestly is just a portion of the huge potential this unique company holds.
https://www.linkedin.com/company/155607/
http://www.otcmarkets.com/stock/ENDV/news/End...48&b=y
http://www.otcmarkets.com/stock/ENDV/news/End...08&b=y
http://www.otcmarkets.com/stock/ENDV/news/End...44&b=y
https://www.linkedin.com/in/collieralan/detai...companies/
Obvious what the connection may be to Charles River Laboratories but a little research into Stemcyte really got me thinking.
Stemcyte is extracting and expanding stem cells derived from umbilical cord blood. As I researched the processes they are using and the expansion rates it was clear how Endonovo could be on the radar of this company. The are using a starch based solution with sugars, proteins and biologics to create a natural replication environment. It is a slow process which is creating 2 dimensional stem cells. They are bragging about an expansion rate of 14-44 fold.
If you are familiar with the Cytotronics platform you know that Endonovo is able to produce biologically superior stem cells in a 6 day period with an 80 fold expansion rate and because they are grown in a non gravitational atmosphere the are 3 dimensional cells.
I wonder if Stemcyte would be interested in doubling their expansion rate in a much quicker time frame. In 2015 Endonovo announces a corporate licensing program which in addition to licensing the technology also sought partnerships for development. They filed patents and continuation patents shortly after.
On Stemcyte's company description under current projects is this statement, "StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies". Now to me there are a few key words in that statement, "involved in" and "new". If this was a project that was solely being run by Stemcyte it would be phrased is developing not involved in development. The new would definitely classify a technology that is less than 2 years old.
Look at the description on the patent Endonovo applied for in Oct 2015.
The perivascular cell mixture (the "Cell Mixture"
is created using the Company's Cytotronics™ platform and the co-culture of immunologically privileged and modulatory stem cells from a portion of the human umbilical cord along with adipose stem cells and a mixture of cord blood cells to create an off-the-shelf therapeutic product that can be stored indefinitely in a low temperature freezer and used to treat blood-related disorders. This patent is right at the 2 year time frame and could be granted any day now.
Some things to ponder as we wait for these preclinical results of the Immunotronics platform, which honestly is just a portion of the huge potential this unique company holds.
https://www.linkedin.com/company/155607/
http://www.otcmarkets.com/stock/ENDV/news/End...48&b=y
http://www.otcmarkets.com/stock/ENDV/news/End...08&b=y
http://www.otcmarkets.com/stock/ENDV/news/End...44&b=y
